ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
ProQR Therapeutics (Nasdaq: PRQR) announces participation in the HC Wainwright Virtual BIOCONNECT 2021 Conference, scheduled for January 11, 2021. The company, focused on developing RNA therapies for inherited retinal diseases, aims to transform lives through its proprietary RNA repair platform. A webcast of the presentation will be available on the ProQR website under the 'Investors & Media' section. ProQR emphasizes its commitment to addressing severe genetic rare diseases such as Leber congenital amaurosis 10 and Usher syndrome.
- Participation in HC Wainwright Virtual BIOCONNECT 2021 Conference, enhancing visibility.
- Focus on RNA therapies for inherited retinal diseases shows commitment to innovation.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming HC Wainwright Virtual BIOCONNECT 2021 Conference. A webcast of the presentation will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under ‘Events’, beginning January 11, 2021.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in these conferences. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 535 7743
hans@lifesciadvisors.com
Media Contact:
Alison Chen
LifeSci Communications
T: +1 646 876 4932
achen@lifescicomms.com
FAQ
What is ProQR Therapeutics known for?
When is ProQR's presentation at the HC Wainwright Conference?
Where can I access the webcast of ProQR's presentation?
What diseases is ProQR targeting with its RNA therapies?
What is the stock symbol for ProQR Therapeutics?
